Taking stock of the drug industry, from the lab to the medicine chest

September 30, 2025 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

Win McNamee/Getty Images Trump strikes deal with Pfizer aimed at lowering prescription drug prices Pfizer to price some drugs in line with costs in other countries, participate in new direct-to-consumer website, and avoid tariffs. By Daniel Payne and Matthew Herper STAT+ | Trump, Pfizer, and the art of a drug pricing deal Friendship, threats, and high-stakes negotiation: Pfizer's Oval Office deal with Trump could slash drug costs and reset U.S. pharma's balance of power. By Matthew Herper STAT+ | Lilly's head scientist discusses its GLP-1 pill, Alzheimer's strategy, and finding promising ideas and startups Q&A with Eli Lilly chief scientific officer Daniel Skovronsky on weight loss drugs, Alzheimer's, and importance of healthy biotech ecosystem By Jonathan Wosen FDA YouTube STAT+ | Top FDA drug regulator's unusual criticism of a therapy gets Wall Street wagging George Tidmarsh, the head of the FDA's CDER division, has a personal connection to Kevin Tang, the largest investor in the company that makes the drug. By Adam Feuerstein Indivior to stop marketing Opvee, controversial overdose-reversal medication Indivior halts Opvee promotion after NY settlement. Critics say the overdose drug is overpriced, risky, and no safer than widely used naloxone. By Lev Facher

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2025, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser